Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

• FDA approval · 2011-01-14
  FDA Approved: TASIGNA — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for Tasigna (nilotinib) by Novartis Pharmaceuticals to modify labeling and/or expand its approved in…

• FDA approval · 2010-10-28
  FDA Approved: DASATINIB — Supplemental Application (Prasco Laboratories)

  FDA approved a supplemental application for dasatinib filed by Prasco Laboratories.

• FDA approval · 2010-03-15
  FDA Approved: TASIGNA — Supplemental Application (Novartis Pharmaceuticals Corporation)

  The FDA approved a supplemental application for Tasigna (nilotinib) filed by Novartis Pharmaceuticals Corporation. The approval updates the …

• FDA approval · 2009-08-21
  FDA Approved: TASIGNA — Supplemental Application (Novartis Pharmaceuticals Corporation)

  The FDA approved a supplemental application for Tasigna (nilotinib) submitted by Novartis, resulting in updated labeling.

• FDA approval · 2007-11-08
  FDA Approved: DASATINIB — Supplemental Application (Prasco Laboratories)

  The FDA approved a supplemental application for dasatinib submitted by Prasco Laboratories.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2006-06-28
  FDA Approved: DASATINIB — Original Application (Prasco Laboratories)

  FDA approved dasatinib under an original application submitted by Prasco Laboratories. The approval covers treatment of Philadelphia chromos…